Merck Wins New KEYTRUDA Approvals as Tulisokibart Clears Phase 3 Test

Merck (NYSE:MRK) announced new FDA approvals for KEYTRUDA (pembrolizumab)-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer. The company also reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody, in moderate-to-severe ulcerative colitis. These developments strengthen Merck's oncology and immunology pipeline.

The Products

KEYTRUDA is a PD-1 inhibitor used in multiple cancer types. The new approvals include:

• Triple-negative breast cancer: Adjuvant treatment with chemotherapy for early-stage disease.
• Muscle-invasive bladder cancer: Adjuvant treatment after surgical resection.

Tulisokibart is an anti-TL1A monoclonal antibody that reduces inflammation in the colon.

Pricing and Availability

Merck has not disclosed pricing details. KEYTRUDA is expected to be available immediately for the new indications, while tulisokibart remains in development.

Competition

KEYTRUDA faces competition from drugs like Opdivo (nivolumab) from Bristol Myers Squibb and Tecentriq (atezolizumab) from Roche. In ulcerative colitis, tulisokibart competes with Entyvio (vedolizumab) and Humira (adalimumab).

Potential Impact on Merck

The new approvals are expected to boost KEYTRUDA revenues, one of Merck's top-selling products. Tulisokibart's success opens opportunities in the inflammatory bowel disease market, potentially reducing reliance on KEYTRUDA in the long term.